Cargando…

An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency

NGLY1 deficiency, a rare disease with no effective treatment, is caused by autosomal recessive, loss-of-function mutations in the N-glycanase 1 (NGLY1) gene and is characterized by global developmental delay, hypotonia, alacrima, and seizures. We used a Drosophila model of NGLY1 deficiency to conduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hope, Kevin A., Berman, Alexys R., Peterson, Randall T., Chow, Clement Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162339/
https://www.ncbi.nlm.nih.gov/pubmed/35653343
http://dx.doi.org/10.1371/journal.pgen.1010228
_version_ 1784719680650346496
author Hope, Kevin A.
Berman, Alexys R.
Peterson, Randall T.
Chow, Clement Y.
author_facet Hope, Kevin A.
Berman, Alexys R.
Peterson, Randall T.
Chow, Clement Y.
author_sort Hope, Kevin A.
collection PubMed
description NGLY1 deficiency, a rare disease with no effective treatment, is caused by autosomal recessive, loss-of-function mutations in the N-glycanase 1 (NGLY1) gene and is characterized by global developmental delay, hypotonia, alacrima, and seizures. We used a Drosophila model of NGLY1 deficiency to conduct an in vivo, unbiased, small molecule, repurposing screen of FDA-approved drugs to identify therapeutic compounds. Seventeen molecules partially rescued lethality in a patient-specific NGLY1 deficiency model, including multiple serotonin and dopamine modulators. Exclusive dNGLY1 expression in serotonin and dopamine neurons, in an otherwise dNGLY1 deficient fly, was sufficient to partially rescue lethality. Further, genetic modifier and transcriptomic data supports the importance of serotonin signaling in NGLY1 deficiency. Connectivity Map analysis identified glycogen synthase kinase 3 (GSK3) inhibition as a potential therapeutic mechanism for NGLY1 deficiency, which we experimentally validated with TWS119, lithium, and GSK3 knockdown. Strikingly, GSK3 inhibitors and a serotonin modulator rescued size defects in dNGLY1 deficient larvae upon proteasome inhibition, suggesting that these compounds act through NRF1, a transcription factor that is regulated by NGLY1 and regulates proteasome expression. This study reveals the importance of the serotonin pathway in NGLY1 deficiency, and serotonin modulators or GSK3 inhibitors may be effective therapeutics for this rare disease.
format Online
Article
Text
id pubmed-9162339
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-91623392022-06-03 An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency Hope, Kevin A. Berman, Alexys R. Peterson, Randall T. Chow, Clement Y. PLoS Genet Research Article NGLY1 deficiency, a rare disease with no effective treatment, is caused by autosomal recessive, loss-of-function mutations in the N-glycanase 1 (NGLY1) gene and is characterized by global developmental delay, hypotonia, alacrima, and seizures. We used a Drosophila model of NGLY1 deficiency to conduct an in vivo, unbiased, small molecule, repurposing screen of FDA-approved drugs to identify therapeutic compounds. Seventeen molecules partially rescued lethality in a patient-specific NGLY1 deficiency model, including multiple serotonin and dopamine modulators. Exclusive dNGLY1 expression in serotonin and dopamine neurons, in an otherwise dNGLY1 deficient fly, was sufficient to partially rescue lethality. Further, genetic modifier and transcriptomic data supports the importance of serotonin signaling in NGLY1 deficiency. Connectivity Map analysis identified glycogen synthase kinase 3 (GSK3) inhibition as a potential therapeutic mechanism for NGLY1 deficiency, which we experimentally validated with TWS119, lithium, and GSK3 knockdown. Strikingly, GSK3 inhibitors and a serotonin modulator rescued size defects in dNGLY1 deficient larvae upon proteasome inhibition, suggesting that these compounds act through NRF1, a transcription factor that is regulated by NGLY1 and regulates proteasome expression. This study reveals the importance of the serotonin pathway in NGLY1 deficiency, and serotonin modulators or GSK3 inhibitors may be effective therapeutics for this rare disease. Public Library of Science 2022-06-02 /pmc/articles/PMC9162339/ /pubmed/35653343 http://dx.doi.org/10.1371/journal.pgen.1010228 Text en © 2022 Hope et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hope, Kevin A.
Berman, Alexys R.
Peterson, Randall T.
Chow, Clement Y.
An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency
title An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency
title_full An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency
title_fullStr An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency
title_full_unstemmed An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency
title_short An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency
title_sort in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and gsk3 as major therapeutic targets for ngly1 deficiency
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162339/
https://www.ncbi.nlm.nih.gov/pubmed/35653343
http://dx.doi.org/10.1371/journal.pgen.1010228
work_keys_str_mv AT hopekevina aninvivodrugrepurposingscreenandtranscriptionalanalysesrevealstheserotoninpathwayandgsk3asmajortherapeutictargetsforngly1deficiency
AT bermanalexysr aninvivodrugrepurposingscreenandtranscriptionalanalysesrevealstheserotoninpathwayandgsk3asmajortherapeutictargetsforngly1deficiency
AT petersonrandallt aninvivodrugrepurposingscreenandtranscriptionalanalysesrevealstheserotoninpathwayandgsk3asmajortherapeutictargetsforngly1deficiency
AT chowclementy aninvivodrugrepurposingscreenandtranscriptionalanalysesrevealstheserotoninpathwayandgsk3asmajortherapeutictargetsforngly1deficiency
AT hopekevina invivodrugrepurposingscreenandtranscriptionalanalysesrevealstheserotoninpathwayandgsk3asmajortherapeutictargetsforngly1deficiency
AT bermanalexysr invivodrugrepurposingscreenandtranscriptionalanalysesrevealstheserotoninpathwayandgsk3asmajortherapeutictargetsforngly1deficiency
AT petersonrandallt invivodrugrepurposingscreenandtranscriptionalanalysesrevealstheserotoninpathwayandgsk3asmajortherapeutictargetsforngly1deficiency
AT chowclementy invivodrugrepurposingscreenandtranscriptionalanalysesrevealstheserotoninpathwayandgsk3asmajortherapeutictargetsforngly1deficiency